about
Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and LipogenesisStriatal microRNA controls cocaine intake through CREB signallingCreb coactivators direct anabolic responses and enhance performance of skeletal muscleThe transcriptional transactivator Tat selectively regulates viral splicing.CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolinLKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitmentFluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring TumorigenesiscAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy In VivoAdaptive Transcriptional Responses by CRTC Coactivators in CancerAberrant Collagen Cross-linking in Human Oral Squamous Cell CarcinomaIdentification of NSDHL mutations associated with CHILD syndrome in oral verruciform xanthomaEngineered BRET-Based Biologic Light Sources Enable Spatiotemporal Control over Diverse Optogenetic SystemsResponse to Letter to the Editor: "Aberrant Collagen Cross-linking in Human Oral Squamous Cell Carcinoma"Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma
P50
Q28118739-9B98AD75-5786-418E-B0A0-C781960C1D70Q28397558-5C6BD81A-8918-44B8-BC87-9BC78B78316BQ28507328-EA5A8D04-7844-48C0-B0FD-CDDC8BF75ABEQ33700143-E6FA0FD5-B7EA-4FFD-869C-56DE8C1DF100Q34060539-F954F435-52B6-4F18-A17E-2E1FAD2BA9F5Q34736608-5EBC79FE-BF9D-4CC1-BF7C-FFC3F28312A8Q35534230-3AF1C599-9DB2-49DC-BD05-56644EC1F326Q36266500-E5CB262A-9400-432A-8D21-56F5A80A6A02Q36342825-0AD7954A-0816-4D48-84E6-3F51A54AD69FQ36951807-E817AFDC-2FCD-4E42-BEA3-3D08E2A613E3Q38451773-D9759A31-0253-4901-BF34-15C0573AE9BFQ64274633-0373B7C2-AA95-4EDB-9966-9DDD4ED9C7F0Q91517636-8FBC25C5-7A20-4F39-B8D4-89935F812B18Q91754969-669FF9C3-E277-4BA7-A264-AE931464A326Q91947640-A021F71C-740A-4ADD-BBD9-AE4AAE5457BDQ91958294-CA1598A8-C166-4FCF-A8B3-9CF6466F2BC1Q92370068-59663B2D-E541-44EE-AC94-E48A1958EEBEQ92757568-0C1C4320-01AD-4B55-BB1C-6CF414BA259E
P50
description
investigador
@es
researcher
@en
name
Antonio L Amelio
@en
type
label
Antonio L Amelio
@en
prefLabel
Antonio L Amelio
@en
P31
P496
0000-0002-6295-2694